Asian Market Highlights 3 Value Stocks With Intriguing Discounted Estimates
The Asian markets have recently shown mixed performance, with technology and semiconductor stocks experiencing volatility amid global economic developments. In this environment, investors are keenly observing stocks that may be undervalued, presenting potential opportunities for those looking to capitalize on discounted estimates. Identifying a good stock often involves assessing its intrinsic value relative to current market conditions, which can reveal promising investment avenues in the region.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Yadea Group Holdings (SEHK:1585) | HK$9.155 | HK$17.84 | 48.7% |
| Visional (TSE:4194) | ¥8946.00 | ¥17793.48 | 49.7% |
| SK oceanplantLtd (KOSE:A100090) | ₩12900.00 | ₩25662.36 | 49.7% |
| Shiyue Daotian Group (SEHK:9676) | HK$4.67 | HK$9.21 | 49.3% |
| Shengda ResourcesLtd (SZSE:000603) | CN¥37.00 | CN¥73.02 | 49.3% |
| Link and Motivation (TSE:2170) | ¥667.00 | ¥1310.71 | 49.1% |
| Karmarts (SET:KAMART) | THB6.70 | THB13.40 | 50% |
| Hubei Three Gorges Tourism Group (SZSE:002627) | CN¥7.15 | CN¥14.23 | 49.8% |
| BuySell TechnologiesLtd (TSE:7685) | ¥3020.00 | ¥5913.96 | 48.9% |
| Acotec Scientific Holdings (SEHK:6669) | HK$6.365 | HK$12.56 | 49.3% |
Let's review some notable picks from our screened stocks.
Tellhow Sci-Tech (SHSE:600590)
Overview: Tellhow Sci-Tech Co., Ltd. specializes in providing military equipment and intelligent power solutions both in China and internationally, with a market cap of CN¥7.39 billion.
Operations: Tellhow Sci-Tech Co., Ltd. generates revenue through its military equipment and intelligent power solutions offered domestically and abroad.
Estimated Discount To Fair Value: 44.6%
Tellhow Sci-Tech is trading at CN¥8.66, significantly below its estimated future cash flow value of CN¥15.64, indicating it is undervalued by more than 20%. Despite recent earnings showing a decline in net income to CN¥88.06 million for the first half of 2026, the company has become profitable this year with strong forecasted annual earnings growth of 53.8%, outpacing the Chinese market's expected growth rate.
- Our expertly prepared growth report on Tellhow Sci-Tech implies its future financial outlook may be stronger than recent results.
- Unlock comprehensive insights into our analysis of Tellhow Sci-Tech stock in this financial health report.
Dizal (Jiangsu) Pharmaceutical (SHSE:688192)
Overview: Dizal (Jiangsu) Pharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for oncology and hematologic disorders, with a market cap of CN¥27.95 billion.
Operations: Dizal (Jiangsu) Pharmaceutical generates revenue through the discovery, development, and commercialization of therapeutics targeting oncology and hematologic disorders.
Estimated Discount To Fair Value: 28.8%
Dizal (Jiangsu) Pharmaceutical is trading at CN¥60.08, below its estimated future cash flow value of CN¥84.41, highlighting significant undervaluation by over 20%. The recent agreement with AstraZeneca for Zegfrovy could enhance cash flows with an upfront US$600 million payment and potential milestone payments up to US$900 million. Despite a volatile share price, Dizal's earnings are forecasted to grow 33.35% annually, with profitability expected within three years.
- The analysis detailed in our Dizal (Jiangsu) Pharmaceutical growth report hints at robust future financial performance.
- Click to explore a detailed breakdown of our findings in Dizal (Jiangsu) Pharmaceutical's balance sheet health report.
Chroma ATE (TWSE:2360)
Overview: Chroma ATE Inc. is involved in the design, assembly, manufacture, sale, repair, and maintenance of software/hardware for computers and peripherals as well as various electronic testing equipment and power supplies across Taiwan, China, the United States, and other international markets; it has a market cap of approximately NT$853.54 billion.
Operations: The company's revenue segments include NT$1.55 billion from the Automatic Equipment Department and NT$65.88 billion from the Measuring Instruments Business.
Estimated Discount To Fair Value: 11%
Chroma ATE is trading at NT$2015, slightly below its estimated future cash flow value of NT$2263.14, reflecting a modest undervaluation. Despite recent share price volatility, the company's earnings are projected to grow significantly at 34.35% annually over the next three years, outpacing market expectations. Recent earnings reports show strong financial performance with net income for Q2 2026 reaching TWD 5,123 million compared to TWD 1,953 million a year ago.
- In light of our recent growth report, it seems possible that Chroma ATE's financial performance will exceed current levels.
- Delve into the full analysis health report here for a deeper understanding of Chroma ATE.
Key Takeaways
- Get an in-depth perspective on all 217 Undervalued Asian Stocks Based On Cash Flows by using our screener here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com